ALS Functional Rating Scale Revised (ALSFRS-R)
ALS Functional Rating Scale Revised · Also known as: ALS FRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
The ALSFRS-R is a 12-item clinician-administered functional rating scale designed to assess disease progression and functional status in amyotrophic lateral sclerosis (ALS). Introduced by Cedarbaum and colleagues in 1999, it expands upon the original ALSFRS by incorporating respiratory function assessment. It is the primary outcome measure in ALS clinical trials and routine clinical monitoring, providing quantitative tracking of disease decline that predicts survival and guides management decisions.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
ALSFRS-R is the mandatory primary outcome measure in all ALS therapeutic trials as stipulated by regulatory agencies (FDA, EMA). It is essential for routine clinical monitoring in ALS clinics to quantify disease progression and guide timing of interventions (feeding tubes, ventilation, palliative care). It is used in natural history studies and cohort research examining prognostic factors, disease heterogeneity, and predictors of survival. It provides objective documentation for disability assessment, insurance claims, and advance care planning discussions. Less suitable when assessment must be made remotely or by untrained personnel; ideally requires direct clinician contact and observation.
Strengths & limitations
- Objective measurement of functional decline enables precise quantification of disease progression and therapeutic benefit independent of subjective perception
- Rate of ALSFRS-R decline is a powerful prognostic marker, stronger than baseline score alone, for predicting survival and informing counseling
- Brief administration (5 minutes) and simple 0-4 rating scale make it practical for routine clinical use and serial monitoring
- Comprehensive coverage of all major functional domains affected by ALS (bulbar, upper limb, lower limb, respiratory), including critical respiratory decline that signals intervention urgency
- Regulatory gold standard—required endpoint in ALS trials, ensuring data comparability and enabling meta-analyses across studies
- Requires direct clinician assessment; cannot be completed by patient self-report alone reliably, limiting remote administration
- Respiratory items (FVC-dependent) may be confounded by non-ALS factors (obesity, restrictive lung disease, diaphragmatic paralysis stage)
- Floor and ceiling effects possible at early disease (many score 48) or advanced disease (many score 0-10), reducing discriminative ability in those ranges
- Inter-rater reliability varies if not standardized training; clinician experience and consistency affect scoring, particularly in subtle functional changes
Frequently asked
What ALSFRS-R score indicates the need for a feeding tube or noninvasive ventilation?
These decisions depend on clinical context, not score alone. Feeding tube consideration typically occurs when Bulbar subscale falls below 9 or the patient reports aspiration risk, weight loss, or swallowing difficulty. Noninvasive ventilation (BiPAP) is usually initiated when FVC falls below 50% predicted or when dyspnea develops. ALSFRS-R <16 suggests respiratory involvement; combined with reduced FVC, it indicates readiness for ventilation discussion. Decisions should involve patient preference, advance directives, and multidisciplinary team input.
How is ALSFRS-R decline rate calculated, and what does a decline of 1 point/month mean?
Decline rate (slope) = (baseline score - current score) / months elapsed. For example, decline from 48 to 44 over 4 months = 1 point/month. Average ALS decline is 0.9-1.5 points/month. A decline of 1 point/month is typical; faster decline (>2 points/month) suggests aggressive disease and poorer prognosis; slower decline (<0.5 points/month) suggests more indolent course. Decline rate predicts survival better than baseline score—rapid decliners die sooner even if baseline score is high.
Can patients self-complete ALSFRS-R, or must a clinician do it?
Clinical assessment is preferred because items require observation (e.g., speech clarity, handwriting, stair climbing). Some motor items can incorporate patient report, but Bulbar items especially benefit from direct observation. In clinical trials, clinician rating is mandatory. In routine practice, if clinician assessment is unavailable, structured patient/caregiver interview with clear operational definitions can provide useful tracking, but reliability is lower than clinician direct assessment.
What is the relationship between ALSFRS-R and the Modified Rankin Scale in ALS?
ALSFRS-R (0-48, functional granularity) and Modified Rankin (0-6, ordinal disability) measure related but distinct constructs. ALSFRS-R is more sensitive to functional change and more responsive in early/mid disease; Rankin captures global dependency in a simpler metric. Some studies use both: ALSFRS-R for precise tracking in trials, Rankin for simplified disability staging. For ALS, ALSFRS-R is far more commonly used and preferred due to greater responsiveness to disease changes.
Sources
- Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999). The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21. DOI: 10.1016/S0022-510X(99)00210-5 ↗
How to cite this page
ScholarGate. (2026, June 3). ALS Functional Rating Scale Revised. ScholarGate. https://scholargate.app/en/neurology/alsfrs-r
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Modified Rankin ScaleNeurology↔ compare
- MSQOL-54Neurology↔ compare
- MSWS-12Neurology↔ compare
- SS-QoLNeurology↔ compare